I have non-relapsing secondary progressive MS,for which no treatment is currently approved. Tolebrutinub is a new treatment that shows promise for nrSPMS by slowing disability progression. This oral BTK inhibitor (a class of medications that target Bruton’s tyrosine kinase (BTK), a protein involved in the development and function of B cells) has been granted Breakthrough Therapy designation by the FDA and is currently under review. The HERCULES trial demonstrated a significant reduction in the risk of confirmed disability progression in participants with nrSPMS.